Secukinumab in plaque psoriasis—results of two phase 3 trials
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. METHODS: In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), we randomly assigned 738 patients (in the ERASURE study) and 1306 patients (in the FIXTURE study) to subcutaneous secukinumab at a dose of 300 mg or 150 mg (administered once weekly for 5 weeks, then every 4 weeks), placebo, or (in the FIXTURE study only) etanercept at a dose of 50 mg (administered twice weekly for 12 weeks, then once weekly). The objective of each study was to show the superiority of secukinumab over placebo at week 12 with respect to the proportion of patients who had a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) and a score of 0 (clear) or 1 (almost clear) on a 5-point modified investigator's global assessment (coprimary end points). RESULTS: The proportion of patients who met the criterion for PASI 75 at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 81.6% with 300 mg of secukinumab, 71.6% with 150 mg of secukinumab, and 4.5% with placebo; in the FIXTURE study, the rates were 77.1% with 300 mg of secukinumab, 67.0% with 150 mg of secukinumab, 44.0% with etanercept, and 4.9% with placebo (P<0.001 for each secukinumab dose vs. comparators). The proportion of patients with a response of 0 or 1 on the modified investigator's global assessment at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 65.3% with 300 mg of secukinumab, 51.2% with 150 mg of secukinumab, and 2.4% with placebo; in the FIXTURE study, the rates were 62.5% with 300 mg of secukinumab, 51.1% with 150 mg of secukinumab, 27.2% with etanercept, and 2.8% with placebo (P<0.001 for each secukinumab dose vs. comparators). The rates of infection were higher with secukinumab than with placebo in both studies and were similar to those with etanercept. CONCLUSIONS: Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov numbers, NCT01365455 and NCT01358578, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An Ab targeting IL-17 (secukinumab) was approved in 2016 to treat moderate-severe plaque psoriasis [54].”
From The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney (2016) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
Pathogenesis and clinical features of psoriasis
Griffiths, C. E., & Barker, J. N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61128-3 · Cited by 2,158
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., Jala, V. R., Zhang, H.-G., Wang, T., Zheng, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.08.001 · Cited by 1,026
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., & Bruce, A. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100123 · Cited by 906
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease
Onishi, R. M., & Gaffen, S. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03240.x · Cited by 894
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Harper, E. G., Guo, C., Rizzo, H., Lillis, J. V., Kurtz, S. E., Skorcheva, I., Purdy, D., Fitch, E., Iordanov, M., & Blauvelt, A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.65 · Cited by 508
Cited by
Items 801–900 of 1,001
Wu, J. J., Merola, J. F., Feldman, S. R., Menter, A., & Lebwohl, M. (2020) · Dermatology and Therapy · doi:10.1007/s13555-020-00373-z · Cited by 28
Singh, R. S. P., Pradhan, V., Roberts, E. S., Scaramozza, M., Kieras, E., Gale, J. D., Peeva, E., Vincent, M. S., Banerjee, A., Fensome, A., et al. (2020) · Clinical and Translational Science · doi:10.1111/cts.12929 · Cited by 30
Rodríguez-Fernández, K., Sanjuan, V. M., Merino‐Sanjuán, M., Martorell, A., Mateu‐Puchades, A., Martí, M. C., & Gras‐Colomer, E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030654 · Cited by 30
“The PK properties of adalimumab and the factors influencing the adalimumab exposure levels in patients with moderate to severe chronic plaque psoriasis from phase II (M02-528) [69] and phase III (REVEAL) [51] clinical trials (Table 2) were characterized by Mostafa et al. [70].”
BackgroundInfluentialSalvador, J. M. O., Saneleuterio-Temporal, M., Magdaleno‐Tapial, J., Pastor, M. V., Pujol‐Marco, C., Sahuquillo‐Torralba, A., Mateu‐Puchades, A., Pitarch-Bort, G., Marí-Ruiz, J.-I., Mataix, J., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.02.062 · Cited by 26
Acosta, E. H., Garriga-Martina, G. G., Suárez‐Pérez, J. A., Martínez‐García, E., & Herrera‐Ceballos, E. (2020) · Dermatologic Therapy · doi:10.1111/dth.13313 · Cited by 26
Gialouri, C. G., Evangelatos, G., & Fragoulis, G. (2022) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.33.1.150 · Cited by 30
T cell-mediated skin-brain axis: Bridging the gap between psoriasis and psychiatric comorbidities
Yang, J., Zhang, S., Wu, Q., Chen, P., Dai, Y., Long, J., Wu, Y., & Lin, Y. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103176 · Cited by 32
Cai, L., Jiang, C., Zhang, G., Fang, H., Wang, J., Li, Y., Xu, H., Xiao, R., Ding, Y., Huang, K., et al. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae062 · Cited by 25
Papp, K. A., Armstrong, A. W., Reich, K., Karunaratne, M., & Valdecantos, W. C. (2015) · American Journal of Clinical Dermatology · doi:10.1007/s40257-015-0161-5 · Cited by 25
“, secukinumab) [9].”
Discovery of N-indanyl benzamides as potent RORγt inverse agonists
Tian, J., Sun, N., Yu, M., Gu, X., Xie, Q., Shao, L., Liu, J., Liu, L., & Wang, Y. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.082 · Cited by 27
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
Galluzzo, M., D’Adamio, S., Massaro, A., Piccolo, A., Bianchi, L., & Talamonti, M. (2019) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s165605 · Cited by 26
Swindell, W. R., Bojanowski, K., & Chaudhuri, R. K. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.07.715 · Cited by 25
Kumar, A. M., Chiou, A. S., Shih, Y., Li, S., & Chang, A. L. S. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19172 · Cited by 25
Crosby, D. A., Glover, L. E., Brennan, E. P., Kelly, P., Cormican, P., Moran, B., Giangrazi, F., Downey, P., Mooney, E. E., Loftus, B., et al. (2020) · Human Reproduction · doi:10.1093/humrep/deaa111 · Cited by 28
A Review of Secukinumab in Psoriasis Treatment
Berg, S. H., Balogh, E. A., Ghamrawi, R. I., & Feldman, S. R. (2020) · Immunotherapy · doi:10.2217/imt-2020-0195 · Cited by 28
IL-37 Expression Is Downregulated in Lesional Psoriasis Skin
Rønholt, K., Nielsen, A. L., Johansen, C., Vestergaard, C., Fauerbye, A., López‐Vales, R., Dinarello, C. A., & Iversen, L. (2020) · ImmunoHorizons · doi:10.4049/immunohorizons.2000083 · Cited by 25
Lindström, U., Glintborg, B., Giuseppe, D. D., Jørgensen, T. S., Guðbjörnsson, B., Grøn, K. L., Provan, S. A., Michelsen, B., Hetland, M. L., Wallman, J. K., et al. (2020) · Lara D. Veeken · doi:10.1093/rheumatology/keaa825 · Cited by 25
Leonardi, C. L., See, K., Burge, R. T., Sun, Z., Zhang, Y., Mallbris, L., Garrelts, A., & Warren, R. B. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02065-w · Cited by 28
Reich, K., Kristensen, L. E., Smith, S. D., Rich, P. A., Sapin, C., Leage, S. L., McKenzie, R., Schuster, C., Riedl, E., & Gooderham, M. (2022) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1202a104 · Cited by 34
Feng, Y., Zhou, B., Wang, Z., Xu, G., Wang, L., Zhang, T., & Zhang, Y. (2022) · International Journal of Clinical Practice · doi:10.1155/2022/2442603 · Cited by 32
“3ere were 11 RCTs that administrated anti-IL-17 agents and placebos [44, 48, 49, 51–55, 67 ] and reported a Candida infection rate of 1.”
Anti-IL 23 biologics for the treatment of plaque psoriasis
Vu, A., Ulschmid, C. M., & Gordon, K. B. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2132143 · Cited by 30
Martora, F., Scalvenzi, M., Battista, T., Fornaro, L., Potestio, L., Ruggiero, A., & Megna, M. (2023) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s418748 · Cited by 27
Celastrol regulates psoriatic inflammation and autophagy by targeting IL-17A
Park, A., & Heo, T.-H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116256 · Cited by 29
Grosskreutz, C. L., Hockey, H., Serra, D. B., & Dryja, T. P. (2015) · Cornea · doi:10.1097/ico.0000000000000627 · Cited by 28
Apremilast for the management of moderate to severe plaque psoriasis
Vangipuram, R., & Alikhan, A. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1293519 · Cited by 28
“The efficacy and safety of ustekinumab was demonstrated in the Psoriasis Followed by Long-Term Extension (PHOENIX) 1 and 2 studies [26,27].”
BackgroundMethodInfluentialEgeberg, A., Iversen, L., Gniadecki, R., Hvid, L., Dam, T. N., Bryld, L. E., & Skov, L. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14200 · Cited by 26
Systemic therapies in atopic dermatitis: The pipeline
Renert‐Yuval, Y., & Guttman‐Yassky, E. (2017) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2017.03.012 · Cited by 29
Ständer, S., Luger, T., Cappelleri, J. C., Bushmakin, A., Mamolo, C. M., Zielinski, M., Tallman, A. M., & Yosipovitch, G. (2017) · Acta Dermato Venereologica · doi:10.2340/00015555-2856 · Cited by 25
Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series
Phung, M., Georgakopoulos, J. R., Ighani, A., Giroux, L., & Yeung, J. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.11.006 · Cited by 25
“The safety findings of this case series are similar to those reported in secukinumab phase 3 clinical trials.(5) Aside from case 13 who developed a common cold after optimization, there seems to be no apparent dose-related difference in incidences of adverse events.”
ResultMerleev, A. A., Marusina, A. I., Ma, C., Elder, J. T., Tsoi, L. C., Raychaudhuri, S. P., Weidinger, S., Wang, E. A., Adamopoulos, I. E., Luxardi, G., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120682 · Cited by 27
Discovery of super soft-drug modulators of sphingosine-1-phosphate receptor 1
Bell, M. E., Foley, D., Naylor, C., Robinson, C., Riley, J., Epemolu, O., Scullion, P., Shishikura, Y., Katz, E., McLean, W. H. I., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.07.044 · Cited by 26
Therapeutic drug monitoring of biologics in psoriasis
Liau, M. M., & Oon, H. H. B. (2019) · Biologics · doi:10.2147/btt.s188286 · Cited by 41
Kridin, K., Schonmann, Y., Solomon, A., Damiani, G. B., Bitan, D. T., Onn, E., Weinstein, O., & Cohen, A. D. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1905766 · Cited by 27
“Relative to placebo, secukinumab displayed a moderate increase in the risk of URI (4), whereas a comparable and lower risk of URIs were evidenced in patients treated with ixekizumab and brodalumab, respectively (5,31).”
BackgroundSelected biologic markers of inflammation and activity of Crohn’s disease
Karczewski, J., Swora-Cwynar, E., Rzymski, P., Poniedziałek, B., & Adamski, Z. (2015) · Autoimmunity · doi:10.3109/08916934.2015.1016221 · Cited by 26
“The pathologic involvement of IL-17 also seems to be proved by the therapeutic effect achieved in clinical trials with anti-IL17A monoclonal antibody in plaque psoriasis [56], psoriatic arthritis [57], ankylosing spondylitis [58], and rheumatoid arthritis [59].”
BackgroundKaczmarska, A., Kwiatkowska, D., Skrzypek, K. K., Kowalewski, Z. T., Jaworecka, K., & Reich, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914734 · Cited by 29
Proft, F. N., Duran, T. İ., Ghoreschi, K., Pleyer, U., Siegmund, B., & Poddubnyy, D. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103638 · Cited by 30
Asukai, K., Kawamoto, K., Eguchi, H., Konno, M., Nishida, N., Koseki, J., Noguchi, K., Hasegawa, S., Ogawa, H., Yamada, D., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4782-y · Cited by 24
Psoriasis and Psoriatic Arthritis: Flip Sides of the Coin?
Boehncke, W. (2016) · Acta Dermato Venereologica · doi:10.2340/00015555-2385 · Cited by 25
“Two of them, secukinumab and ixekizumab, have shown superior efficacy in the treatment of PsO compared with etanercept (37, 38), the former also in comparison to ustekinumab (39).”
BackgroundOkubo, Y., Ohtsuki, M., Morita, A., Yamaguchi, M., Shima, T., Tani, Y., Nakagawa, H., & Subgroup, E. S. J. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.14761 · Cited by 24
Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris
Palazzo, G. (2020) · Oxford Medical Case Reports · doi:10.1093/omcr/omz134 · Cited by 24
“In general, secukinumab has been shown to be effective and well tolerated in treatment of plaque psoriasis [3].”
BackgroundAtaseven, A., Temiz, S. A., Eren, G., Özer, İ., & Dursun, R. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1801975 · Cited by 24
“In one study, the effects of IL inhibitors on PASI in the treatment of psoriasis were shown to be more successful than anti-TNF treatments (7).”
BackgroundLo, Y., Li, C.-S., Chen, H.-L., Chiang, C.-Y., Huang, C.-C., Tu, T.-J., Lo, T.-H., Choy, D. F., Arron, J. R., Chen, H., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.07.021 · Cited by 24
“The concept that IL-17A is the main driver of psoriasis pathogenesis is consolidated by the finding that almost half of the patients with psoriasis can achieve PASI 90, 90% improvement, after treatment with IL-17Aebased therapies (Langley et al., 2014; Lebwohl et al., 2015; Papp et al., 2018).”
BackgroundAkiyama, S., Cotter, T. G., & Sakuraba, A. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i19.2312 · Cited by 27
Hong, J. J., Hadeler, E. K., Mosca, M., Brownstone, N. D., Bhutani, T., & Liao, W. J. (2022) · Journal of Psoriasis and Psoriatic Arthritis · doi:10.1177/24755303211047479 · Cited by 27
Gooderham, M., Pinter, A., Ferris, L. K., Warren, R. B., Zhan, T., Zeng, J., Soliman, A. M., Kaufmann, C., Kaplan, B., Photowala, H., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18010 · Cited by 27
Ramos, M. J. M., Sánchez‐Piedra, C., González, O. M., Rodríguez‐Lozano, C., Pérez-García, C., Freire, M., Campos, C., Cáliz-Cáliz, R., Calvo-Gutiérrez, J., Blanco-Madrigal, J. M., et al. (2022) · Rheumatology and Therapy · doi:10.1007/s40744-022-00446-9 · Cited by 24
An update on emerging immunological targets and their inhibitors in the treatment of psoriasis
Parab, S. B., & Doshi, G. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109341 · Cited by 30
Kuo, H., Chen, C., Hsu, A. Y., Wang, Y., Lin, C., Hsia, N., Tsai, Y., & Wei, J. C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1302293 · Cited by 24
“Notably, therapies directed at these pathways have demonstrated success in treating diseases such as psoriasis, psoriatic arthritis and Crohn ’ s disease (38, 39), owing to the similarly shared IL-17/IL-23 signaling pathways from among these conditions.”
Cauli, A., Piga, M., Floris, A., & Mathieu, A. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s62870 · Cited by 24
“In the first one, patients were randomized to receive subcutaneous Secukinumab at doses of 300 or 150 mg once weekly for 5 weeks and then every 4 weeks compared with placebo.(42) PASI75 was reached at week 12 by 81.”
MethodWolf, P. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14341 · Cited by 25
Augustin, M., Abeysinghe, S., Mallya, U. G., Qureshi, A. A., Roskell, N., McBride, D., Papavassilis, C., & Gelfand, J. M. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13478 · Cited by 26
Blauvelt, A., Reich, K., Mehlis, S. L., Vanaclocha, F., Sofen, H. L., Abramovits, W., Zhao, Y., Gilloteau, I., Davenport, E. K., Williams, N., et al. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14391 · Cited by 26
Bianchi, E., & Rogge, L. (2019) · Microbes and Infection · doi:10.1016/j.micinf.2019.06.009 · Cited by 27
Endotypes of chronic rhinosinusitis
Yip, J., Monteiro, E., & Chan, Y. (2018) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0000000000000503 · Cited by 30
Jordan, S. C., Choi, J., & Vo, A. A. (2015) · Immunotherapy · doi:10.2217/imt.15.10 · Cited by 25
Translational opportunities for targeting the Th17 axis in acute graft-vs.-host disease
Malard, F., Gaugler, B., Lamarthée, B., & Mohty, M. (2016) · Mucosal Immunology · doi:10.1038/mi.2015.143 · Cited by 27
Huang, Y., Fan, Y., Liu, Y., Xie, W., & Zhang, Z. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04595-1 · Cited by 25
Domizio, J. D., & Gilliet, M. F. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.04.020 · Cited by 28
“These discoveries were initially made in the context of expression studies, showing high levels of IL-17A in skin lesions of plaque psoriasis (Kryczek et al., 2008; Lowes et al., 2008), and later confirmed by the efficacy of treatments targeting IL-17A (Langley et al., 2014) or its receptor (Papp et al., 2012).”
BackgroundInfluential30 Years of Biotherapeutics Development—What Have We Learned?
Ghilardi, N., Pappu, R., Arron, J. R., & Chan, A. C. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101619-031510 · Cited by 27
Reich, K., Körber, A., Mrowietz, U., Sticherling, M., Sieder, C., Früh, J., & Bachhuber, T. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19398 · Cited by 23
Chapurin, N., Li, P., Chandra, R. K., Turner, J. H., & Chowdhury, N. I. (2020) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22652 · Cited by 24
Huang, H., Cai, M., Hong, X., Zheng, L., Hu, Z., Yuan, T., Li, W., Sheng, Y., & Zhang, X.-J. (2020) · European Journal of Dermatology · doi:10.1684/ejd.2020.3878 · Cited by 23
Skin manifestations in spondyloarthritis
Meier, K., Schloegl, A., Poddubnyy, D., & Ghoreschi, K. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20975915 · Cited by 27
Ultra‐high‐frequency ultrasound monitoring of plaque psoriasis during ixekizumab treatment
Dini, V., Janowska, A., Faita, F., Panduri, S., Benincasa, B. B., Izzetti, R., Romanelli, M., & Oranges, T. (2021) · Skin Research and Technology · doi:10.1111/srt.12942 · Cited by 23
Cytokine responses in nonlesional psoriatic skin as clinical predictor to anti-TNF agents
Tsoi, L. C., Patrick, M. T., Shuai, S., Sarkar, M. K., Chi, S., Ruffino, B., Billi, A. C., Xing, X., Uppala, R., Zang, C., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.07.024 · Cited by 27
Gut microbiome in multiple myeloma: Mechanisms of progression and clinical applications
Zhang, L., Xiang, Y., Li, Y., & Zhang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1058272 · Cited by 29
“In addition, anti-17A monoclonal antibodies and anti-IL5 antibodies have been approved for the treatment of immunomodulatory diseases such as psoriasis (97) and eosinophilic asthma (98).”
BackgroundKoné‐Paut, I., Mannes, I., & Dusser, P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020453 · Cited by 26
Piperine ameliorates psoriatic skin inflammation by inhibiting the phosphorylation of STAT3
Lu, H. J., Gong, H., Du, J., Gao, W., Xu, J. F., Cai, X., Yang, Y., & Xiao, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110221 · Cited by 25
Secukinumab (AIN457) for the treatment of psoriasis
López‐Ferrer, A., Vilarrasa, E., & Puig, L. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1095092 · Cited by 27
“Serious AEs were experienced by 6, 5 and 6% of patients who received 300 mg secukinumab, 150 mg secukinumab and etanercept, respectively [35].”
BackgroundMethodInfluentialReview of IL-17 inhibitors for psoriasis
Amin, M., Darji, K., No, D. J., Bhutani, T., & Wu, J. J. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1395796 · Cited by 27
“In ERASURE (N¼ 738) and FIXTURE (N¼ 1306), participants were randomized to receive secukinumab 150mg or 300mg (once a week for five weeks, followed by every four-week dosing), placebo, or (in FIXTURE only) etanercept 50mg (twice a week for 12weeks, then once weekly thereafter) for 12weeks (7).”
BackgroundMethodInfluentialMechanisms and functions of IL-17 signaling in renal autoimmune diseases
Schmidt, T., Luebbe, J., Paust, H., & Panzer, U. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.09.005 · Cited by 24
Biologic therapy in psoriasis: navigating the options.
McKay, C., Kondratuk, K. E., Miller, J. P., Stumpf, B., & Boh, E. (2018) · PubMed · Cited by 26
Wang, K., Zhang, Z., Liu, K., Yang, X., Zou, H., Zhou, J., Miao, X., Chen, W., Xiong, L., & Wen, Y. (2018) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2018.10.020 · Cited by 25
Biological and synthetic target DMARDs in psoriatic arthritis
Silvagni, E., Bortoluzzi, A., Ciancìo, G., & Govoni, M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104473 · Cited by 23
Mashiko, S., Edelmayer, R. M., Bi, Y., Olson, L. M., Wetter, J. B., Wang, J., Maari, C., Proulx, É. S., Kaimal, V., Li, X., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.09.027 · Cited by 25
Ghazawi, F. M., Lim, M. M., Dutz, J. P., & Kirchhof, M. G. (2020) · International Journal of Dermatology · doi:10.1111/ijd.15028 · Cited by 23
Mrowietz, U., Warren, R. B., Leonardi, C., Saure, D., Petto, H., Hartz, S., Dossenbach, M. R. K., & Reich, K. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17130 · Cited by 25
Torres, T. R., Barcelos, A., Filipe, P., & Fonseca, J. E. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.618163 · Cited by 24
“ERASURE (25) Langley 2014 738 SEC 150mg 567 YES SEC 300mg”
InfluentialHoughton, K., Patil, D., Gomez, B., & Feldman, S. R. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00564-2 · Cited by 22
Blauvelt, A., Gooderham, M., Griffiths, C. E. M., Armstrong, A. W., Zhu, B., Burge, R. T., Gallo, G., Guo, J., Garrelts, A., & Lebwohl, M. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00690-5 · Cited by 22
“Sensitivity analysis was conducted by evaluating the normalized AUC at Week 52 for 8 of the 18 studies in the primary analysis that maintained randomization from baseline to 48 or 52 weeks: AMAGINE-2 [19], AMAGINE-3 [19], CLEAR [18], FIXTURE [20], IXORA-S [21], UltIMMa-1 [22], UltIMMa-2 [22], and ECLIPSE [23].”
MethodInfluentialTreatments for psoriasis: A journey from classical to advanced therapies. How far have we reached?
Hari, G., Kishore, A., & Pai, K. S. R. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175147 · Cited by 21
Clinical Efficacy and Safety of Anti-IL-17 Agents for the Treatment of Patients with Psoriasis
Chen, Y., Qian, T., Zhang, D., Yan, H., & Hao, F. (2015) · Immunotherapy · doi:10.2217/imt.15.50 · Cited by 24
The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis
Lerman, M. A., & Rabinovich, C. E. (2015) · Pediatric Drugs · doi:10.1007/s40272-015-0128-2 · Cited by 26
“While phase III trials for its effectiveness for plaque psoriasis and its superiority to etanercept were reported in late 2014, there are no other reports of its use in uveitis [105].”
BackgroundWorley, S. L. (2016) · PubMed Central · Cited by 27
Consensus on the management of patients with psoriatic arthritis in a dermatology setting
Gisondi, P., Altomare, G. F., Ayala, F., Conti, A., Dapavo, P., SIMONE, C. D., Foti, C., Idolazzi, L., Lubrano, E., Malara, G., et al. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14741 · Cited by 22
von Csiky-Sessoms, S., & Lebwohl, M. (2019) · Dermatologic Clinics · doi:10.1016/j.det.2018.11.001 · Cited by 35
Émond, B., Ellis, L., Chakravarty, S. D., Ladouceur, M., & Lefèbvre, P. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1620713 · Cited by 23
Adiponectin levels in a large pooled plaque psoriasis study population
Gerdes, S., Pinter, A., Biermann, M. H. C., Papavassilis, C., & Reinhardt, M. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1621979 · Cited by 22
“into this pooled post-hoc analysis (17,18).”
Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis
Azevedo, A., & Torres, T. R. (2016) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2016.09.021 · Cited by 24
Autoinflammation and HLA-B27: Beyond Antigen Presentation
Sibley, C. H. (2016) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2016.1175641 · Cited by 22
“The first studies of IL-23 and IL-17 blockade were in psoriasis, where overwhelmingly positive results were achieved.(88,89) These drugs were then studied in psoriatic arthritis where similarly positive results were found although the results were less robust.”
ResultCutaneous Immune Cell-Microbiota Interactions Are Controlled by Epidermal JunB/AP-1
Uluçkan, Ö., Jiménez, M., Roediger, B., Schnabl, J., Díez-Córdova, L. T., Troulé, K., Weninger, W., & Wagner, E. F. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.042 · Cited by 21
Advances in Psoriasis Research: Decoding Immune Circuits and Developing Novel Therapies
Wang, L., Liu, R., Tang, Y.-L., Ma, Y.-F., Wang, G., Ruan, Q., & Zheng, S. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189233 · Cited by 34
“However, their long-term use may be associated with increased risks of drug resistance and infections [13,14].”
Advances in use of immunomodulatory agents—a rheumatology perspective
Her, M., & Kavanaugh, A. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.65 · Cited by 25
Pathophysiological basis of systemic treatments in psoriasis
Volc, S., & Ghoreschi, K. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13050 · Cited by 26
Contemporary management of moderate to severe plaque psoriasis.
Wu, J. J. (2017) · PubMed · Cited by 27
The Immune System and Pathogenesis of Melanoma and Non-melanoma Skin Cancer
Schrom, K. P., Kim, I., & Baron, E. D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-46227-7_11 · Cited by 25
Novel Analgesics with Peripheral Targets
Ciotu, C. I., & Fischer, M. J. M. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00937-z · Cited by 23
Tricyclic-Carbocyclic RORγt Inverse Agonists—Discovery of BMS-986313
Yang, M. G., Bertrand, M. B., Xiao, Z., Marcoux, D., Weigelt, C. A., Yip, S. H., Wu, D., Ruzanov, M., Sack, J. S., Wang, J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01992 · Cited by 22
Megna, M., Patruno, C., Bongiorno, M. R., Gambardella, A., Guarneri, C., Foti, C., Lembo, S., Loconsole, F., & Fabbrocini, G. (2022) · Journal of Dermatological Treatment · doi:10.1080/09546634.2022.2062280 · Cited by 21
Yamanaka‐Takaichi, M., Ghanian, S., Katzka, D. A., Torgerson, R. R., & Alavi, A. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00686-z · Cited by 27
“from trial to trial, but the most common dosing schedule was weekly administration until week 4, and then q4w [12, 16, 17, 19, 21].”
Metadata
- Authors
- Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., Rivas, E., Tsai, T.-F., Wasel, N., Tyring, S., Salko, T., Hampele, I., Notter, M., Karpov, A., Helou, S., & Papavassilis, C.
- Affiliations
- Dalhousie University (CA)
- University of Alabama at Birmingham (US)
- Mount Sinai Hospital (US)
- Dermatologikum Hamburg (DE)
- Manchester Academic Health Science Centre (GB)
- Probity Medical Research (CA)
- Hospital de Sant Pau (ES)
- Jikei University School of Medicine (JP)
- University of Iceland (IS)
- National Taiwan University (TW)
- Center for Clinical Studies (US)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-24
- Volume
- 371
- Issue
- 4
- Pages
- 326-338
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1973354423
- Cited by
- 1,997
- References
- 25
- Citations by year
- 2026: 96 · 2025: 107 · 2024: 116 · 2023: 142 · 2022: 146 · 2021: 165 · 2020: 198 · 2019: 230 · 2018: 201 · 2017: 223 · 2016: 203 · 2015: 146 · 2014: 19
- FWCI
- 90.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (acceptedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- GRO (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- secukinumab, plaque psoriasis, IL-17A, anti-IL-17A monoclonal antibody, etanercept, PASI 75, dosing regimen, biologic therapy, treatment efficacy and safety, erasure, fixtures, Psoriasis Area and Severity Index
- MeSH terms
- Etanercept, Adult, Antibodies, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Immunoglobulin A, Immunoglobulin G, Immunosuppressive Agents, Infections, Injections, Subcutaneous, Male, Middle Aged, Psoriasis, Receptors, Tumor Necrosis Factor, Interleukin-17, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.